RecruitingNCT06038019
Thresholds In Food Allergy evaluaTion And predictioN
Thresholds In Food Allergy evaluaTion And predictioN, a Prospective, Multicentre Registry Study
Sponsor
Hamilton Health Sciences Corporation
Enrollment
2,000 participants
Start Date
Nov 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Thresholds In food allergy evaluaTion And predictioN, a prospective, observational registry. The aim is to quantify food allergy thresholds in Canada and their clinical predictors.
Eligibility
Min Age: 3 MonthsMax Age: 65 Years
Inclusion Criteria2
- Suspicion or history of food allergy based on medical history, positive skin prick test, and/or serum food-specific IgE. A suggestive history is defined as typical clinical signs and/or symptoms (urticaria, angioedema, abdominal pain, vomiting, dyspnea, wheeze) within 60 minutes of the ingestion of a food.
- Ability to discontinue all antihistamines for 1 week before oral food challenge.
Exclusion Criteria4
- Previous desensitization treatment to a food allergen
- Allergies to any component of the oral challenge vehicle
- Unstable conditions including uncontrolled asthma or chronic urticaria
- Any clinically significant disease/chronic medical condition which may interfere with study evaluations.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTOral food challenge
Patients will undergo oral food challenge with increasing amounts of food allergen
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06038019
Related Trials
Stepwise Heat-Denaturated Protein Introduction for Tolerance Induction in Food Allergy
NCT063806735 locations
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
NCT063694677 locations
Natural History and Genetics of Food Allergy and Related Conditions
NCT025048531 location
Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases
NCT065299132 locations
Omalizumab Weight-Based Dosing Efficacy Trial
NCT069435343 locations